Page last updated: 2024-12-05

neostibosan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Neostibosan is an antimonial drug used for the treatment of leishmaniasis, a parasitic disease. It is a complex of antimony potassium tartrate (also known as tartar emetic) and gluconic acid. Neostibosan is administered intravenously or intramuscularly. The mechanism of action of neostibosan is not fully understood, but it is thought to involve the inhibition of the parasite's enzymes and the production of reactive oxygen species. Neostibosan is effective in treating visceral leishmaniasis, the most severe form of the disease. However, it has a number of side effects, including nephrotoxicity, cardiotoxicity, and hepatotoxicity. It is also associated with the development of drug resistance. Neostibosan is still widely used in many parts of the world, but it is being replaced by newer, more effective and safer drugs in some countries. Neostibosan remains an important drug for the treatment of leishmaniasis, particularly in resource-limited settings.'

Cross-References

ID SourceID
PubMed CID11135
SCHEMBL ID153722
MeSH IDM0115419

Synonyms (18)

Synonym
neostibosan
4-stibonobenzenamine
p-aminobenzenestibonic acid
693b
4-aminobenzenestibonic acid
stibanilic acid
aniline, p-stibono-
benzenamine, 4-stibono-
(4-aminophenyl)stibonic acid
unii-2hbu9hp3ek
554-76-7
2hbu9hp3ek ,
SCHEMBL153722
DTXSID00203953
astaril; bayer 693; ethylstibamine
Q27254749
STARBLD0000921
AKOS040753242
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.69 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index107.18 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (47.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]